Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?

Rheumatology (Oxford). 2021 Apr 6;60(4):e136-e138. doi: 10.1093/rheumatology/keaa657.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Clinical Decision-Making
  • Dermatomyositis / drug therapy*
  • Humans
  • Janus Kinase Inhibitors / therapeutic use*
  • Nitriles
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Treatment Outcome

Substances

  • Janus Kinase Inhibitors
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib